This approval was accompanied by the VENTANA FOLR1 (FOLR-2.1) RxDx Assay, an immunohistochemical test used to identify FRα-positive tumors through moderate-to-strong membrane staining in at least 75% of tumor cells. The gene discussed is FOLR1; the disease is neoplasm.